Roche's innovative anti-anemia agent CERA (Continuous Erythropoietin Receptor Activator) was able to control anemia in patients with chronic kidney disease (CKD) not on dialysis within a narrow target range set out in expert guidelines for more than one year. The Phase II extension data presented for the first time at the American Society of Nephrology 38th Annual Meeting & Scientific Exposition - Renal Week meeting in Philadelphia today...Technorati Tags: CERA, Roche, Anemia
I'm Dr. Joshua Schwimmer, a nephrologist and internal medicine physician in New York City. • Kidney Notes was the first active nephrology blog. (Trivia: Kidney Notes is so old that the National Library of Medicine still uses it as an example of how to formally cite blogs.) • Professionally, you can find me at Kidney.nyc. • Kidney Notes is for educational purposes only, not medical advice. Consult qualified health care professionals. See disclaimer.
Saturday, November 12, 2005
Study of CERA (Continuous Erythropoietin Receptor Activator) in Kidney Disease Patients Demonstrates Control of Anemia
Via PRNewswire: